智通财经APP讯，国药科技股份(08156)公布截至2025年6月30日止年度业绩，收入约6130万港元，同比增加约48%。公司拥有人应占亏损约90万港元，同比大幅减少约95%。每股亏损0.19港仙。
公告称，收入增长主要由于大健康产品市场需求增加及供应链服务营运效率提高，突显公司对该等核心业务领域的战略重点的有效性。
董事会认为集团于本年度财务业绩显著改善乃主要由于以下各项的净影响，其中包括：(i)由于业务改善，毛利同比增长约920万港元或184%;(ii)加强行政及营运开支的成本控制;(iii)于本年度，贷款资本化收益约390万港元;及(iv)由于本年度的贷款资本化，融资成本减少。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.